The U.S. Food and Drug Administration has revoked the Emergency Use Authorization for bamlanivimab administered alone, bamlanivimab and etesevimab administered together, and REGEN-COV. The agency authorized revised fact sheets for health care providers to include additional information on susceptibility of SARS-CoV-2 variants to each of the monoclonal antibody therapies that are available through an Emergency Use Authorization for the treatment of COVID-19. The FDA said it is providing this information to equip health care providers with the most current data so they can make informed decisions and provide appropriate care to patients with COVID-19. Among the makers of these treatments are Eli Lilly’s (LLY), AbCellera (ABCL), Vir Biotechnology (VIR), GSK (GSK) and Regeneron (REGN).
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Resmed Stock Sees Alarming Drop Alongside a New Obstructive Sleep Apnea Treatment Rival
- Eli Lilly Stock Jumps on FDA Approval of Obstructive Sleep Apnea Treatment
- Eli Lilly announces FDA approval for Zepbound for obstructive sleep apnea
- Eli Lilly announces FDA approval for Zepbound
- BMO lowers Novo Nordisk price target to $105, says reaction to data ‘overdone’